51. 全身性強皮症
［臨床試験数：466，薬物数：536（DrugBank：142），標的遺伝子数：110，標的パスウェイ数：210］
Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-004718-32-NL (EUCTR) | 09/10/2020 | 09/10/2020 | Stem cell transplantation in diffuse cutaneous systemic sclerosis: upfront therapy or rescue therapy after failure of immunosuppressants? | Upfront autologous hematopoietic stem cell transplantation versus immunosuppressive medication in early diffuse cutaneous systemic sclerosis: an international multicentre, open-label, randomized controlled trial | Diffuse cutaneous systemic sclerosis according to the ACR/EULAR criteria;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Mycophenolate mofetil | UMC Utrecht | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 4 | Netherlands | ||
| 2 | NCT04244916 (ClinicalTrials.gov) | May 25, 2020 | 6/1/2020 | MPA AUC Monitoring in Patients Receiving MMF for Diffuse Cutaneous or Pulmonary Involvement in Systemic Sclerosis | Prospective Study to Investigate the Relevance of Monitoring Area Under the Curve of Mycophenolic Acid in Patients Receiving Mycophenolate Mofetil to Treat a Diffuse Cutaneous or a Pulmonary Involvement of Systemic Sclerosis | Systemic Sclerosis | Biological: AUC of MPA measure | Assistance Publique - Hôpitaux de Paris | NULL | Recruiting | 18 Years | N/A | All | 50 | France | |
| 3 | NCT03678987 (ClinicalTrials.gov) | September 13, 2018 | 13/9/2018 | Mycophenolate Mofetil Pharmacokinetics in Systemic Sclerosis | Mycophenolate Mofetil in Systemic Sclerosis: A Phase 1 Pharmacokinetic Study of Orally Ingested Mycophenolate Mofetil Tablets in Patients Suffering From Systemic Sclerosis | Systemic Sclerosis;Gastrointestinal Complication | Diagnostic Test: P-MPA concentration;Drug: mycophenolic acid | Region Skane | NULL | Completed | 18 Years | N/A | All | 35 | Phase 1 | Sweden |
| 4 | NCT03221257 (ClinicalTrials.gov) | November 28, 2017 | 12/7/2017 | Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate | Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease | Scleroderma, Systemic;Interstitial Lung Disease | Drug: Pirfenidone (PFD);Drug: Placebo (Plac);Drug: Mycophenolate Mofetil (MMF) | Michael Roth | University of Michigan;Genentech, Inc.;University of California, Los Angeles | Active, not recruiting | 18 Years | N/A | All | 150 | Phase 2 | United States |
| 5 | NCT02896205 (ClinicalTrials.gov) | October 2016 | 27/8/2016 | Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease | A Randomized Controlled Trial to Compare the Efficacy of Oral Mycophenolate Mofetil With Placebo in Patients With Systemic Sclerosis Related Early Interstitial Lung Disease | Systemic Sclerosis;Scleroderma;Interstitial Lung Disease | Drug: Mycophenolate mofetil;Drug: Placebo | Postgraduate Institute of Medical Education and Research | NULL | Completed | 18 Years | N/A | All | 41 | Phase 3 | India |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT02370693 (ClinicalTrials.gov) | March 2016 | 11/2/2015 | Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis | Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis Grant Number: R34HL122558 | Interstitial Lung Disease;ILD;Systemic Sclerosis;Scleroderma | Drug: Bortezomib;Drug: Placebo;Drug: Mycophenolate mofetil | Northwestern University | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | United States |
| 7 | NCT01413100 (ClinicalTrials.gov) | September 15, 2011 | 8/8/2011 | Scleroderma Treatment With Autologous Transplant (STAT) Study | A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis | Systemic Scleroderma | Biological: Anti-Thymocyte Globulin;Procedure: Autologous Hematopoietic Stem Cell Transplantation;Drug: Cyclophosphamide;Biological: Filgrastim;Other: Laboratory Biomarker Analysis;Drug: Mycophenolate Mofetil;Procedure: Peripheral Blood Stem Cell Transplantation;Drug: Plerixafor;Other: Quality-of-Life Assessment;Other: Questionnaire Administration | Fred Hutchinson Cancer Research Center | National Cancer Institute (NCI) | Active, not recruiting | N/A | 70 Years | All | 20 | Phase 2 | United States;Canada |
| 8 | NCT02339441 (ClinicalTrials.gov) | June 2010 | 22/12/2014 | Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis | Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis | Early Diffuse Cutaneous Systemic Sclerosis | Drug: Methotrexate;Drug: Mycophenolate mofetil;Drug: Cyclophosphamide | University of Manchester | NULL | Completed | 18 Years | N/A | Both | 320 | N/A | NULL |
| 9 | NCT01047072 (ClinicalTrials.gov) | January 2010 | 11/1/2010 | Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis | Phase II Clinical Trial of Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis | Systemic Scleroderma | Drug: fludarabine phosphate;Radiation: total-body irradiation;Drug: tacrolimus;Drug: mycophenolate mofetil;Biological: rituximab;Drug: cyclophosphamide;Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;Procedure: peripheral blood stem cell transplantation | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | National Cancer Institute (NCI) | Withdrawn | 18 Years | 65 Years | Both | 0 | Phase 2 | United States |
| 10 | NCT00883129 (ClinicalTrials.gov) | September 2009 | 16/4/2009 | Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) | Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II) | Scleroderma;Interstitial Lung Disease | Drug: Mycophenolate mofetil;Drug: Cyclophosphamide;Drug: Placebo | Michael Roth | National Heart, Lung, and Blood Institute (NHLBI);Hoffmann-La Roche | Completed | 18 Years | N/A | All | 142 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT00622895 (ClinicalTrials.gov) | September 1, 2006 | 22/2/2008 | Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis | Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis | Systemic Scleroderma;Severe Systemic Sclerosis | Drug: fludarabine phosphate;Drug: Mycophenolic Acid;Drug: tacrolimus;Radiation: total-body irradiation;Procedure: bone marrow transplantation;Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation;Procedure: quality-of-life assessment;Other: laboratory biomarker analysis;Other: flow cytometry;Procedure: biopsy | Fred Hutchinson Cancer Research Center | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | N/A | 70 Years | All | 3 | Phase 1;Phase 2 | United States |
| 12 | NCT00333437 (ClinicalTrials.gov) | May 2006 | 2/6/2006 | Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement | Pulmonary Involvement in Scleroderma: Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients | Scleroderma, Systemic | Drug: Mycophenolate mofetil | University of California, San Francisco | Roche Pharma AG | Completed | 21 Years | 70 Years | All | 7 | N/A | United States |
| 13 | NCT00433186 (ClinicalTrials.gov) | March 2006 | 7/2/2007 | Mycophenolate Mofetil in Systemic Sclerosis | Phase I, Open-label Study of Mycophenolate Mofetil In Systemic Sclerosis | Diffuse Cutaneous Systemic Sclerosis | Drug: Mycophenolate Mofetil | Boston University | Aspreva Pharmaceuticals | Completed | 18 Years | N/A | Both | 30 | Phase 1 | United States |